Mas Rina Wati Haji Abdul Hamid

Dr. Mas Rina Wati Haji Abdul Hamid

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 1998 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
RJReiner U. Jänicke
Reiner U. Jänicke
MSMichael L. Sprengart
Michael L. Sprengart
MHMas Rina Wati Haji Abdul Hamid
Mas Rina Wati Haji Abdul Hamid
APAlan G. Porter
Alan G. Porter
Interleukin 1β-converting enzyme-like proteases (caspases) are crucial components of cell death pathways. Among the caspases identified, caspase-3 stands out because it is commonly activated by numerous death signals and cleaves a variety of important cellular proteins. Studies in caspase-3 knock-out mice have shown that this protease is essential for brain development. To investigate the requirement for caspase-3 in apoptosis, we took advantage of the MCF-7 breast carcinoma cell line, which we show here has lost caspase-3 owing to a 47-base pair deletion within exon 3 of the CASP-3 gene. This deletion results in the skipping of exon 3 during pre-mRNA splicing, thereby abrogating translation of theCASP-3 mRNA. Although MCF-7 cells were still sensitive to tumor necrosis factor (TNF)- or staurosporine-induced apoptosis, no DNA fragmentation was observed. In addition, MCF-7 cells undergoing cell death did not display some of the distinct morphological features typical of apoptotic cells such as shrinkage and blebbing. Introduction of the CASP-3 gene into MCF-7 cells resulted in DNA fragmentation and cellular blebbing following TNF treatment. These results indicate that although caspase-3 is not essential for TNF- or staurosporine-induced apoptosis, it is required for DNA fragmentation and some of the typical morphological changes of cells undergoing apoptosis.

1 December 2008 in Experimental Cell Research
Verified
Journal Article
Closed access
SDSuwarni Diah
Suwarni Diah
GZGuo-Xing Zhang
Guo-Xing Zhang
YNYukiko Nagai
Yukiko Nagai
WZWei Zhang
Wei Zhang
LGLiu Gang
Liu Gang
HHHirofumi Hitomi
Hirofumi Hitomi

29 September 2022 in Frontiers in Pediatrics
Verified
Journal Article
Open access
SSSyahirah Amnani Suhaimi
Syahirah Amnani Suhaimi
IZIhsan Nazurah Zulkipli
Ihsan Nazurah Zulkipli
HGHazim Ghani
Hazim Ghani
MHMas Rina Wati Haji Abdul Hamid
Mas Rina Wati Haji Abdul Hamid
Thalassemias are a group of inherited blood disorders that affects 5–7% of the world population. Comprehensive screening strategies are essential for the management and prevention of this disorder. Today, many clinical and research laboratories have widely utilized next-generation sequencing (NGS) technologies to identify diseases, from germline and somatic disorders to infectious diseases. Yet, NGS application in thalassemia is limited and has just recently surfaced due to current demands in seeking alternative DNA screening tools that are more efficient, versatile, and cost-effective. This review aims to understand the several aspects of NGS technology, including its most current and expanding uses, advantages, and limitations, along with the issues and solutions related to its integration into routine screening and diagnosis of thalassemias. Hitherto, NGS has been a groundbreaking technology that offers tremendous improvements as a diagnostic tool for thalassemia in terms of its higher throughput, accuracy, and adaptability. The superiority of NGS in detecting rare variants, solving complex hematological problems, and providing non-invasive alternatives to neonatal diagnosis cannot be overlooked. However, several pitfalls still preclude its use as a stand-alone technique over conventional methods.

1 October 2002 in Transgenic Research
Verified
Journal Article
Closed access
PDF file
MBMelissa A. Brown
Melissa A. Brown
HNHans Nicolai
Hans Nicolai
KHKathy Howe
Kathy Howe
TKToyomasa Katagiri
Toyomasa Katagiri
ELEl-Nasir Lalani
El-Nasir Lalani
ESEllen Solomon
Ellen Solomon

1 May 1997 in Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression
Verified
Journal Article
Closed access
MHMas Rina Wati Haji Abdul Hamid
Mas Rina Wati Haji Abdul Hamid
TTThirumaran Thanabalu
Thirumaran Thanabalu
APAlan G Porter
Alan G Porter

4 April 2024 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
NBNurul Wafiqah Saipol Bahrin
Nurul Wafiqah Saipol Bahrin
SMSiti Nur Idayu Matusin
Siti Nur Idayu Matusin
AMAklimah Mustapa
Aklimah Mustapa
LHLu Zen Huat
Lu Zen Huat
SPSriyani Perera
Sriyani Perera
MHMas Rina Wati Haji Abdul Hamid
Mas Rina Wati Haji Abdul Hamid
Background: Breast cancer incidence has been on the rise significantly in the Asian population, occurring at an earlier age and a later stage. The potential predictive value of molecular subtypes, biomarkers, and genetic variations has not been deeply explored in the Asian population. This study evaluated the effect of molecular subtype classification and the presence or absence of biomarkers and genetic variations on pathological complete response (pCR) after neoadjuvant treatment in Asian breast cancer patients. Methods: A systematic search was conducted in MEDLINE (PubMed), Science Direct, Scopus, and Cochrane Library databases. Studies were selected if they included Asian breast cancer patients treated with neoadjuvant chemotherapy and contained data for qualitative or quantitative analyses. The quality of the included studies was assessed using the Newcastle Ottawa Scale. Following the random effects model, pooled odds ratios or hazard ratios with 95% confidence intervals for pCR were analysed using Review Manager Software. Heterogeneity between studies was assessed using Cochran’s Q-test and I2 test statistics. Results: In total, 19,708 Asian breast cancer patients were pooled from 101 studies. In the neoadjuvant setting, taxane-anthracycline (TA) chemotherapy showed better pCR outcomes in triple-negative breast cancer (TNBC) (p<0.0001) and human epidermal growth factor receptor 2 enriched (HER2E) (p<0.0001) than luminal breast cancer patients. Similarly, taxane-platinum (TP) chemotherapy also showed better pCR outcomes in TNBC (p<0.0001) and HER2E (p<0.0001). Oestrogen receptor (ER)-negative, progesterone receptor (PR)-negative, HER2-positive and high Ki-67 were significantly associated with better pCR outcomes when treated with either TA or TP. Asian breast cancer patients harbouring wildtype PIK3CA were significantly associated with better pCR outcomes when treated with TA in the neoadjuvant setting (p=0.001). Conclusions: In the neoadjuvant setting, molecular subtypes (HER2E and TNBC), biomarkers (ER, PR, HER2, HR, Ki-67, nm23-H1, CK5/6, and Tau), and gene (PIK3CA) are associated with increased pCR rates in Asian breast cancer patients. Hence, they could be further explored for their possible role in first-line treatment response, which can be utilised to treat breast cancer more efficiently in the Asian population. However, it needs to be further validated with additional powered studies. Systematic review registration: PROSPERO CRD42021246295.